Table 2 Patients’ characteristics and oral mucositis severity
Patient | Age (y) | Sex | PS | Disease | Chemotherapy regimen | Radiation therapy | Concomitant drugs or therapies | Mucositis severity CTCAE v3 (Grade) |
|---|---|---|---|---|---|---|---|---|
1 | 59 | M | 0 | Stomach cancer | Capecitabine | N | Lidocaine gargle | 2 |
2 | 75 | M | 0 | Hard plate cancer | N | Brachytherapy (70 Gy) | Lidocaine gargle, Low-level laser therapy | 2 |
3 | 67 | M | 0 | Tongue cancer | Cisplatin, Fluorouracil, Cetuximab | N | Lidocaine gargle | 2 |
4 | 38 | F | 0 | Acute myeloid leukemia | Allotransplantation | N | Morphine hydrochloride hydrate, lidocaine gargle | 3 |
5 | 60 | F | 0 | Appendix cancer | Panitumumab | N | Salcote® capsule | 2 |
6 | 80 | M | 0 | Renal cell cancer | Pembrolizumab | N | Dexartin® oral ointment | 2 |
7 | 71 | M | 1 | Pharyngeal cancer | Cisplatin | 70 Gy | N | 2 |
8 | 38 | F | 2 | Acute myeloid leukemia | Cyclophosphamide | N | N | 2 |
9 | 55 | F | 0 | Stomach cancer | Ramucirumab, paclitaxel | N | Lidocaine gargle, triamcinolone acetonide | 2 |
10 | 68 | F | 0 | Adult T-cell leukemia | Fludarabine phosphate, Busulfan | Total Body Radiation (2 Gy) | Dexartin® oral ointment, lidocaine | 2 |